TriangleNCT02552121 · OUTCOME
Part 1: Progression Free Survival (PFS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- weeks
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Baseline to end of follow-up; maximum time of follow-up was 24 weeks
What was measured
Progression-free survival was defined as the time in weeks from date of first dose until the date of disease progression or death, whichever is earliest.
Groups in this outcome
Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg
Tisotumab vedotin 0.9 mg/kg was administered as an intravenous infusion, over a minimum of 30 minutes, 3 times every 4 weeks (3q4wk).
Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
Tisotumab vedotin 1.2 mg/kg was administered as an intravenous infusion, over a minimum of 30 minutes, 3 times every 4 weeks (3q4wk).
| Group | Source count |
|---|---|
| Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | 2 |
| Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg | 1 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | 11.3 | Not reported | 7.3 | 15.3 | Not reported |
| Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg | NA | Not reported | 7.1 | NA | Could not be estimated due to the low number of events disease progression or death. |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 7.3
- upper Limit
- 15.3
- value
- 11.3
- comment
- Could not be estimated due to the low number of events disease progression or death.
- group Id
- OG001
- lower Limit
- 7.1
- upper Limit
- NA
- value
- NA
- denoms
- counts
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 1
- units
- Participants
- description
- Progression-free survival was defined as the time in weeks from date of first dose until the date of disease progression or death, whichever is earliest.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Tisotumab vedotin 0.9 mg/kg was administered as an intravenous infusion, over a minimum of 30 minutes, 3 times every 4 weeks (3q4wk).
- id
- OG000
- title
- Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg
- description
- Tisotumab vedotin 1.2 mg/kg was administered as an intravenous infusion, over a minimum of 30 minutes, 3 times every 4 weeks (3q4wk).
- id
- OG001
- title
- Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- Baseline to end of follow-up; maximum time of follow-up was 24 weeks
- title
- Part 1: Progression Free Survival (PFS)
- type
- SECONDARY
- unit Of Measure
- weeks
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice